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ORIGINAL ARTICLE
Proline-Rich Homeodomain protein (PRH/HHEX)
is a suppressor of breast tumour growth
RM Kershaw1, D Roberts1, J Wragg1, AM Shaaban1, E Humphreys1, J Halsall1, L Price1, R Bicknell1, K Gaston2 and P-S Jayaraman1
Breast tumours progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). PRH/HHEX
(proline-rich homeodomain/haematopoietically expressed homeobox) is a transcription factor that displays both tumour
suppressor and oncogenic activity in different disease contexts; however, the role of PRH in breast cancer is poorly understood.
Here we show that nuclear localization of the PRH protein is decreased in DCIS and IBC compared with normal breast. Our previous
work has shown that PRH phosphorylation by protein kinase CK2 prevents PRH from binding to DNA and regulating the
transcription of multiple genes encoding growth factors and growth factor receptors. Here we show that transcriptionally inactive
phosphorylated PRH is elevated in DCIS and IBC compared with normal breast. To determine the consequences of PRH loss of
function in breast cancer cells, we generated inducible PRH depletion in MCF-7 cells. We show that PRH depletion results in
increased MCF-7 cell proliferation in part at least due to increased vascular endothelial growth factor signalling. Moreover, we
demonstrate that PRH depletion increases the formation of breast cancer cells with cancer stem cell-like properties. Finally, and in
keeping with these ﬁndings, we show that PRH overexpression inhibits the growth of mammary tumours in mice. Collectively, these
data indicate that PRH plays a tumour suppressive role in the breast and they provide an explanation for the ﬁnding that low PRH
mRNA levels are associated with a poor prognosis in breast cancer.
Oncogenesis (2017) 6, e346; doi:10.1038/oncsis.2017.42; published online 12 June 2017
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a non-invasive breast carcinoma
with increasing incidence. It comprises a proliferation of neoplastic
epithelial cells within mammary ducts with or without lobular
involvement. DCIS can progress over time to invasive breast
carcinoma (IBC).1 Breast cancer formation and progression occurs
through random changes in genes and gene expression, resulting
in clonal expansion of those cells that have an advantageous
phenotype. Tumour-initiating cells have stem cell-like properties
and are also known as cancer stem cells (CSC). In current models
of breast tumour progression, CSC are believed to be derived from
transit-amplifying cell populations that exist within normal
mammary stem cell differentiation. The transit-amplifying cells
are more highly proliferative than true mammary stem cells, but
they are still capable of self-renewal and differentiation along
multiple lineages, (reviewed in Chaffer and Weinberg2 and Ye and
Weinberg3). An important property of CSC is that they can
produce differentiated progeny, that is, bulk cancer cells without
self-renewal properties, and this differentiation is reversible so
the bulk cancer cells can dedifferentiate back towards CSC.4,5
Members of the Zeb, Twist, Slug and Sox9 transcription factor
families are known to promote morphological changes known as
epithelial to mesenchymal transition, whereby epithelial cells
acquire a mesenchymal phenotype and become elongated and
migratory. Although this alteration was initially believed to be
associated with tumour progression towards invasion, it is now
also linked with tumour initiation and progression as the
same factors promote CSC formation (reviewed in Ye et al.6).
Transcription factors from the Zeb family, for example, regulate
the expression of the CSC marker CD44 and govern the propensity
of breast cells from different lineages to become CSC.7
PRH/HHEX (proline-rich homeodomain/haematopoietically
expressed homeobox) is a DNA-binding protein that regulates
the development of multiple tissues in the embryo and tissue
homoeostasis in the adult. PRH misregulation is associated with a
variety of cancers and leukaemias (reviewed in Gaston et al.8 and
Souﬁ and Jayaraman9). Although PRH can function as an
oncogene in some subtypes of leukaemia, it has been shown to
possess tumour suppressor activity in acute myeloid leukaemia
cells and in liver tumour cells (reviewed in Gaston et al.8).
PRH regulates cell proliferation via multiple mechanisms. PRH
directly regulates the transcription of several genes encoding
growth factors, such as VEGFA, growth factor receptors, including
FLT1 (VegfR1) and KDR (VegfR2) and inhibits VEGF autocrine
signalling.10,11 It also regulates the transcription of genes
encoding growth factor co-receptors, such as the TGFβ
co-receptor Endoglin, to control cell proliferation and cell
migration.12 The DNA-binding activity of PRH is inhibited
following the phosphorylation of amino acids in the PRH
homeodomain by protein kinase CK2, preventing the regulation
of these genes.11 In addition, PRH interacts directly with a variety
of transcription factors and translation factors involved in the
control of cell proliferation, including c-Myc, eIF4E and PML,
modulating their activity and/or their intracellular localization.13–16
Decreased nuclear localization of PRH has been observed in
invasive breast ductal and lobular carcinomas (IBC).17 Here we use
immunohistochemistry (IHC) and observe decreased nuclear PRH
in human breast tumours and alterations in phosphorylated PRH
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in tumours compared with normal mammary epithelial cells. We
demonstrate that PRH regulates breast cell proliferation and that
PRH overexpression inhibits mammary tumour growth in mice.
RESULTS
PRH expression and phosphorylation is altered in primary breast
tumours
We examined PRH and pPRH expression in 14 normal breast
sections, 7 DCIS and 13 IBC cases using IHC (Figure 1 and
Summarized in Table 1). Figure 1 shows representative images in
which either PRH or pPRH are stained red (NovaRed substrate) and
cell nuclei are counterstained blue with haematoxylin. The tissue
samples were assessed for cytoplasmic and nuclear PRH and pPRH
staining across the whole slide and categorized into low
percentage (0–10), intermediate percentage (11–70) or high
percentage (71–100) of cells with positive staining. In addition,
the intensity of staining was similarly categorized into very weak,
weak, intermediate or strong (Table 1). The IHC analysis was
performed by a specialist breast pathologist. In normal breast, PRH
is present in both the nucleus and the cytoplasm of ductal
epithelial cells (Figure 1a). In DCIS and IBC there is weak
PRH staining in the nuclei in 7/7 and 10/12 cases, respectively
(Figures 1c and e). Some invasive carcinomas also show strong or
Figure 1. PRH and pPRH in normal breast, DCIS and invasive breast carcinoma. Representative images showing PRH and pPRH expression in
normal breast (a and b: × 100 magniﬁcation), DCIS (c and d: × 200 magniﬁcation) and invasive carcinoma (e and f: × 200 magniﬁcation)
determined using IHC. Total PRH was detected using the M6 monoclonal antibody at 1:2000 dilution (a, c, e). pPRH was detected using the
YKN5 antibody at 1:3000 dilution (b, d, f) as described in the text. In b the inset shows the pPRH immunoreactivity of myoepithelial cells (M)
and the weak pPRH immunoreactivity of luminal epithelial cells (E). (g, h) Show negative controls of normal tissue stained using mouse and
rabbit IgG, respectively (×200 magniﬁcation).
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intermediate cytoplasmic PRH staining intensity, but this is
variable and also present in some DCIS (2/7) and some apparently
normal samples (2/13). Phosphorylated PRH staining is generally
very weak in the cytoplasm and nuclei of normal luminal epithelial
cells (Figure 1b). However, pPRH is strongly expressed in
surrounding myoepithelial cells (inset, Figure 1b) and in some
normal breast samples (3/12). Most DCIS cases show strong
nuclear pPRH expression and the majority of nuclei are stained
(Figure 1d). A statistical comparison of categorical data for staining
intensity for normal breast, DCIS and IBC and a similar analysis of
categorical data for area stained for normal breast, DCIS and IBC
showed that there is a highly signiﬁcant decrease in the
percentage of nuclei stained for PRH (P= 2× 10− 3) and decreased
nuclear staining intensity (P= 2× 10− 4) in tumours compared with
normal breast tissue and a trend towards increased cytoplasmic
staining. There is also a statistically highly signiﬁcant increase in
the percentage of nuclei stained for pPRH (P= 7.14 × 10− 3) and in
the intensity of staining (P= 4.76 × 10− 3) in DCIS compared with
normal tissue. Although a similar trend is observed in IBC
compared with normal, this was not statistically signiﬁcant. These
data conﬁrm that PRH is less nuclear in breast carcinomas and is
similar to the data previously reported by Puppin et al.17
Moreover, these data show that transcriptionally inactive pPRH
is dramatically increased in DCIS and also elevated in IBC.
PRH regulates the proliferation of MCF-7 cells
To examine the role of PRH in breast cells we overexpressed
the protein in human breast adenocarcinoma MCF-7 cells using an
adenoviral vector expressing Myc-tagged PRH and examined the
effects on cell number in MTT cell viability assays. Infection with
Table 1. A summary of the immunohistochemistry data for pPRH and PRH
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Ad-PRH resulted in a decrease in cell number with time compared
with cells infected with empty adenovirus (Figure 2a). Western
blotting conﬁrmed expression of Myc-PRH in the Ad-PRH-infected
cells (Figure 2a, inset). We have observed previously that transient
PRH knockdown (KD) in MCF-7 cells increases cell number.10 To
conﬁrm this we made use of an isopropyl β-d-1-thiogalactopyr-
anoside (IPTG)-inducible lentiviral vector expressing PRH shRNA to
knockdown PRH expression. Three independent PRH KD cell lines
or control cell lines (transduced using IPTG-inducible control
shRNA expressing viruses) were generated from MCF-7 cells to
ensure that the sites of viral integration differ in each cell line. PRH
KD in IPTG-treated MCF-7 cells transduced with the inducible PRH
shRNA vector was observed using western blotting (Figure 2b,
inset). PRH KD in these independent cell lines resulted in increased
cell number in MTT cell viability assays (Figure 2b) and increased
cell proliferation as measured using a BrdU incorporation assay
(Figure 2c). Moreover, propidium iodide staining of DNA content
and ﬂow cytometry showed that in the PRH KD cells there
is a decrease in the percentage of cells in G1 and an increase
in the percentage of cells in S-phase (Figure 2d). In contrast,
PRH overexpression in MCF-7 cells resulted in a signiﬁcant
decrease in the number of viable cells and an increase in
apoptosis (Figure 2e). These results clearly demonstrate that PRH
negatively regulates the proliferation of MCF-7 breast cancer cells.
PRH overexpression can also inhibit the proliferation of
MDA-MB-231 breast cancer cells. In these cells PRH overexpression
resulted in an increase in the percentage of cells in G1
(Supplementary Figure S1A) and a reduction in cell proliferation
as measured by BrdU incorporation (Supplementary Figure S1B).
PRH regulates the expression of proliferation-, angiogenesis- and
CSC-related genes
To better understand which genes are regulated by PRH in breast
cells, we performed mRNA microarray experiments (Figure 3a). In
total, 2299 genes were signiﬁcantly upregulated and 2681 genes
downregulated following PRH KD (fold change 41.5 statistical
analysis of microarray false discovery rate Po0.05). Interestingly,
GO pathway analysis (GATHER) revealed that 165 genes associated
with the term cell cycle (GO:000074), 55 genes associated with the
term proliferation (GO:0042127) and 20 genes associated with the
Figure 2. PRH regulates the proliferation of MCF-7 cells. (a) MCF-7 cells were infected with control adenovirus (empty symbols) or an
adenovirus expressing Myc-tagged PRH (ﬁlled symbols) at an MOI of 50. The number of viable cells was determined using an MTT assay at the
time points indicated post-infection. Mean and standard deviation (s.d.) from n= 3 independent experiments each performed in triplicate. The
inseted panel shows a western blot for Myc-PRH in the infected cells 24 h post-infection with Lamin A/C as a loading control. (b) MCF-7
control and PRH KD cell lines were induced with IPTG for 7 days. Cell number was then determined by MTT assay over 72 h. (mean and s.d.,
n= 3 independent experiments). The inseted panel shows a western blot for PRH (M6 antibody) at day 7 post-induction and with Tubulin as a
loading control. (c) Cell proliferation following PRH KD was determined by BrdU incorporation 7 days post-induction. The graph shows the
percentage of BrdU-positive cells (mean and s.d., n= 3, *Student’s t-test Po0.05). (d) PRH KD and control cells 7 days post-induction were dual
stained with PI/AV (APC antibody) and analysed by ﬂow cytometry. The graph shows the percent distribution of cells in each stage of the cell
cycle (mean and s.d., n= 3). (e) MCF-7 cells were incubated with control Ad or Ad-PRH for 4 days before being stained with 10 μg/μl propidium
iodide and 5 μl of Annexin V-APC antibody (BD Biosciences - Europe, Oxford, UK). Cells were then analysed by ﬂow cytometry to determine
live cells (PI− , AV− ) or apoptotic cells (PI− , AV+ or PI+, AV+) (n= 3, two-tail homoscedastic t-test *Po0.05).
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term angiogenesis (GO:0001525) were signiﬁcantly upregulated in
the PRH KD cells including VEGFA and VEGFC. Additionally genes
known to encode CSC markers (CD44, CD24 and ITGA6) were
signiﬁcantly altered. Selected genes are shown in a heat map
(Figure 3a). To validate the microarray data quantitative RT–PCR
was performed on several altered genes encompassing a wide
range of fold change in expression values: CCND2 (x179), NRP1
(x3), ENG (x12), VEGFA (5 transcripts x1.8–x3.5) and VEGFC (x3.5).
In each case the mRNAs were altered in accordance with the
change observed in the microarray data (Figures 3b and c).
Since VEGFA, VEGFC, NRP1 and VEGFR2 are altered in the
microarray data and upregulation of KDR (VegfR2) and VEGFA has
been observed by us before in transient PRH KD experiments,10
we set out to determine whether inducible PRH KD also results in
cells that have an altered autocrine response to VEGF signalling.
We carried out MTT cell viability assays with MCF-7 control and
MCF-7 PRH KD cells in the presence and absence of a VEGF
antibody18 (Figure 3d). PRH KD cell numbers decreased upon
addition of the VEGF antibody whereas control cell numbers were
not signiﬁcantly altered (Figure 3d). Since cell number is reduced
by the VEGF antibody only in PRH KD cells, we conclude that
increased VEGF autocrine signalling contributes to the increased
proliferation of these PRH KD cells.
To determine whether any of the genes upregulated in the PRH
KD cells are downregulated during PRH overexpression, MCF-7
cells were infected with Ad-PRH or an empty adenovirus as
described above and RNA extracted for microarray experiments.
The results of Myc-tagged PRH overexpression on selected genes
are presented in Supplementary Figure S2. Expression of Myc-PRH
downregulated 2633 genes and upregulated 1913 genes (fold
change 41.5 statistical analysis of microarray false discovery rate
Po0.05). GO analysis (GATHER) showed that 41 cell cycle
(GO:0007049) and 8 angiogenesis genes (GO:00001525) are
downregulated upon PRH overexpression including VEGFC
(× 0.32) and NRP1 (× 0.47). To validate the overexpression
microarray the expression of VEGFC and NRP1 was examined
using quantitative PCR and shown to be downregulated in
agreement with the microarray data (Figure 3e). VEGFC expression
has recently been shown to be correlated with mammary tumour
proliferation19,20 and VEGFC falls within the subset of 414 genes
that are inversely regulated, that is upregulated in PRH KD but
downregulated by PRH overexpression. Changes in VEGFC may
therefore contribute to the growth phenotype observed upon
perturbation of PRH levels.
PRH knockdown promotes the formation of CSC-like cells
Our microarray studies showed that PRH KD cells have altered
expression of CD44 and CD24 genes and also of breast
CSC-related genes such as Sox9 and ITGA6 (Figure 3a). Flow
cytometry analysis showed that there is a dramatic increase in the
CD44hi/CD24lo population in PRH KD cell lines compared with
controls (Figures 4a and b) corresponding to the changes in gene
expression in the microarray (Figure 3a). These data suggest
that the PRH KD population contains an increased number of cells
with a CSC-like gene expression pattern. To further examine the
formation of these CSC-like cells, we performed mammosphere
formation assays under non-adherent conditions. Signiﬁcantly
more mammospheres (450μm size particles) were produced by
MCF-7 PRH KD cells compared with controls when seeded at
20 000 cells/well but this was not observed at a lower cell density,
possibly due to altered autocrine cell signalling at high cell
Figure 3. Altered gene expression in MCF-7 PRH KD cells. (a) mRNA expression data are presented as a matrix in which rows represent
individual genes, and columns represent individual mRNA samples from three independent control (C1–C3) and PRH KD (KD1–KD3) cell lines.
The relative level of gene expression is depicted according to the colour scale shown. From 4980 differentially expressed genes selected genes
with known function in angiogenesis/cell proliferation, cell cycle, growth factors and breast stem cell markers are shown. (b) Relative
expression of CCN2 (Cyclin D2) was determined by RT–PCR normalized to GAPDH mRNA (n= 3. Student’s t-test, ***Po0.001). (c) Relative
expression of CDH1 (E-Cadherin), ENG (Endoglin), NRP1 (Neuropilin), VEGFC and VEGFA was determined as above (n= 3, Student’s t-test,
*Po0.05, **Po0.01, ***Po0.001). (d) Control cells and PRH KD MCF-7 cells were grown in the absence or presence of VEGF antibody. Cell
number was determined using an MTT assay (n= 3, Student’s t-test, *Po0.05). (e) The relative expression of NRP1 (Neuropilin) and VEGFC in
MCF-7 cells infected with empty Adenovirus (Ad) and Ad-PRH was determined by RT–PCR normalized to GAPDH mRNA (n= 3, Student’s t-test,
*Po0.05, **Po0.01, ***Po0.001).
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densities (Figure 4c). Limited dilution assays were performed to
examine secondary mammosphere formation21 and these assays
conﬁrm that the PRH-depleted cells are better able to form
mammospheres as judged by the steep initial gradient for PRH KD
cells compared with control cells (Figure 4d). However, at higher
cell numbers there is departure from a linear relationship for the
PRH KD cells suggestive of altered cell adhesion. Interestingly the
PRH KD mammospheres are large extended structures that
are very different in appearance from the compact spherical
structures produced by control cells (Figure 4e). We conclude that
PRH depletion results in increased formation of CSC-like cells
and/or CSC progeny (amplifying progenitors) that retain the
stem cell marker phenotype (CD44hi/CD24lo) and that these cells
contribute to the large mammosphere-like particles.
To determine whether overexpression of PRH inhibits formation
of the CSC-like cells, we infected MCF-7 cells with Ad-PRH
or control virus and determined the number of primary mammo-
spheres formed 7 days post-infection. As expected, overexpres-
sion of PRH decreased the number of mammospheres formed
(Figure 4f). However, PRH overexpression did not alter expression
of CD44 and CD24 marker proteins in cells prior to mammosphere
formation at 48 h post-infection as measured using ﬂow cytometry
(Supplementary Figure S3). In summary, downregulation of PRH
leads to increased expression of CD44 and decreased expression
of CD24 and increased mammosphere formation in limiting
dilution analysis. Although overexpression of PRH leads to
formation of fewer mammospheres, CD44 and CD24 are not
altered under these conditions. This suggests that the reduction of
mammosphere number following PRH overexpression may be
indirect through an inhibitory effect on cell proliferation rather
than a direct effect on CSC genes.
PRH can act as a breast tumour suppressor
To directly examine the importance of PRH activity in tumour
growth we overexpressed PRH in mouse mammary tumour cells.
We used murine 4T1 mammary tumour cells for these experi-
ments because when they are introduced orthotopically into
syngeneic mice they are capable of rapid tumour initiation.
Figure 4. PRH levels inﬂuence mammosphere formation. MCF-7 control and PRH KD cell lines were induced with IPTG for 7 days then analysed
by ﬂow cytometry. (a) Flow cytometry analysis of the CSC markers CD24 and CD44. (b) Quantiﬁcation of CD24loCD44hi cells (n= 4, Student’s
t-test, ***Po0.005). (c) Quantiﬁcation of primary mammospheres formed by control and PRH KD MCF-7 cells (n= 3, Student’s t-test, *Po0.05).
(d) Limiting dilution analysis with secondary MCF-7 control and PRH KD mammospheres counted at day 14, (n= 5). (e) Mammospheres and
mammosphere-like particles were imaged under optical light (mag. × 10). (f) Quantiﬁcation of primary mammospheres formed by control and
PRH overexpressing MCF-7 cells (n= 3, Student’s t-test, *Po0.05).
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Thus 4T1 cells expressing luciferase (4T1-12B cells) are useful for
non-invasive imaging of in vivo tumour growth.22 We modiﬁed the
4T1 cell line to express high levels of luciferase using a lentiviral-
luciferase expression vector (creating 4T1L cells). As expected,
PRH overexpression in 4T1L cells reduced cell number in vitro
(Figure 5a). Western blotting shows that the Myc-tagged PRH
protein is highly expressed in the 4T1L cells 48 h post-infection
(Figure 5a). Orthotopic injection of 4T1L cells into the mammary
fat pad of syngeneic BALB/C mice resulted in tumours that formed
within 8–12 days (Figure 5b). However 4T1L cells overexpressing
PRH produced signiﬁcantly smaller tumours than control cells
(Figures 5b and 5c). These data suggest that PRH has a tumour
suppressor role in breast epithelial cells.
Low PRH mRNA expression correlates with decreased breast
cancer survival
Since PRH expression is altered in breast cancer cells and PRH
depletion in MCF-7 cells results in increased cell proliferation and
increased formation CSC-like cells, we examined public databases
for evidence linking PRH expression to breast tumour formation
and breast tumour progression. The Kaplan–Meier plotter
database contains survival information and mRNA expression
data for breast tumour patients.23 Figure 5d shows a Kaplan–Meier
plot generated from these data. Low expression of PRH mRNA
in breast tumour patients across all breast tumour subtypes
correlates with a poorer relapse-free survival compared with
patients expressing higher levels of PRH (P410−14). A similar
outcome was observed using the Gene Expression-Based Out-
come for Breast Cancer Online (GOBO) database24 (Supplementary
Figure S4). Consistent with these data interrogation of the MethHC
database that reports on DNA methylation and mRNA expression
shows that the HHEX (PRH) gene is hypermethylated in
breast cancer (Supplementary Figure S5A) and that increased
methylation is associated with lower mRNA expression
(Supplementary Figure S5B). Thus, HHEX gene expression appears
to be downregulated in breast cancer cells and this is associated
with a poor outcome.
DISCUSSION
The PRH protein is known to regulate the proliferation of multiple
cell types, including haematopoietic lineages, vascular cells and
liver hepatocytes. Decreased nuclear localization of PRH has been
observed in thyroid tumours and in subtypes of acute myeloid
leukaemia and in both ductular and lobular IBCs.16,17,25 In liver
cancer cells, PRH overexpression downregulates tumour growth in
mouse xenograft models and PRH antagonizes c-Myc activity.13,26
In well-differentiated liver tumours, there is little nuclear PRH
expression and strong cytoplasmic expression, whereas in poorly
differentiated tumours there is lower cytoplasmic expression
of PRH. However, not all tumours follow this trend in that a
fraction of poorly differentiated tumours show high nuclear PRH
Figure 5. PRH overexpression decreases tumour growth. (a) Left—number of 4T1L cells 6 days after infection with Ad-PRH. Cells infected with
Ad-PRH or empty adenovirus (Ad) were plated at equal numbers at 24 h and viable cells were counted at day 6 post-infection (n= 3, Student’s
t-test *Po0.05). Right—Western blot with 4T1L cells infected with Ad or Ad-PRH for 48 h. Lamin A/C as a loading control. (b) Tumour volumes
as calculated by caliper measurements (width ×height × depth) for each time point following injection of Ad-PRH or Ad-infected 4T1L cells
into BALB/C mice (n= 10, Student’s t-test, Po0.001 at day 22, combined data from two independent experiments). (c) Tumours were excised
from the mice in (b) and weighed (n= 10, **Po0.01). (d) Kaplan–Meier survival plot for PRH expression and probability of survival: black= low
expression, grey=high expression. Logrank test P= 1.1− 10− 15.
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expression.26 Thus, it is not yet clear whether a reduction in PRH
expression accompanies a loss in differentiation in this tumour
type. In prostate cells PRH plays a tumour suppressor role.
We have demonstrated that decreasing active PRH in immorta-
lized prostate epithelial cells promotes both cell proliferation
and cell migration.27 Moreover, we have demonstrated that pPRH
is elevated in prostate cancer cell lines, in benign prostatic
hyperplasia and prostatic adenoarcinoma compared with normal
controls.27 Thus, loss of nuclear localization, decreased PRH
expression and elevated phosphorylation of PRH are associated
with tumourigenesis.
Examination of PRH expression and localization in a cohort of
primary breast tissues samples using IHC shows that PRH protein
is present in normal breast tissues in nuclear and cytoplasmic
compartments but is less strongly nuclear and more cytoplasmic
in DCIS and IBC. These results are broadly in agreement with the
observations of Damante and co-workers;17 however, they did not
measure PRH levels in normal breast tissues or in in situ
carcinomas and used different antibodies so direct comparisons
are difﬁcult. Phosphorylated PRH is present only at low levels in
the cytoplasm of normal primary breast epithelial cells but pPRH
becomes greatly elevated in the nuclei of luminal epithelial cells in
DCIS and elevated to a lesser extent in IBC. One possible
explanation for the increased pPRH observed is that increased
inactivation of PRH occurs when these cells proliferate,
whereas when they become invasive, they may show increased
phosphorylation in conjunction with decreased expression and/or
altered subcellular localization. Larger sample sizes are required to
allow an investigation of PRH and PRH phosphorylation status
with tumour progression.
In agreement with the hypothesis that PRH is a growth control
protein in breast cells that is inactivated during tumour
progression, we have shown that PRH overexpression inhibits
mammary tumour growth in a mouse model of breast cancer.
In previous studies we showed that PRH overexpression in
MDA-MB-231 breast cancer cells also inhibits cell migration and
signiﬁcantly reduces the ability of these cells to invade Matrigel
in vitro.12 We have shown here that inducible knockdown of PRH
in MCF-7 breast tumour cells results in additional tumorigenic
properties including increased cell proliferation, due in part to
increased expression of cell cycle genes, to increased autocrine
VEGF signalling through VEGFA and most likely VEGFC, and
increased mammosphere forming frequency. Indeed VEGFC is
known to increase CSC formation through autocrine signalling via
NRP2 in Claudin-low breast cells.28 In culture CSC are in a dynamic
equilibrium between CSC and non-CSC daughter cells through
autoregulatory inﬂammatory IL6- and IL-8-dependent feedback
loops.4,29 The MCF-7 PRH KD cells have increased expression of
both IL-8 (× 33) and IL6 (× 2.7) (microarray data). Thus, autocrine
signalling through these cytokines and increased autocrine
survival signalling through growth factors such as VEGFA and
VEGFC are likely to contribute cumulatively to the stable increase
in cells with a CSC marker phenotype and to altered mammo-
sphere formation.
Together these data support the notion that PRH is a breast
tumour suppressor and that its nuclear activity may be
compromised in breast tumour cells by increased PRH phosphor-
ylation and/or decreased PRH mRNA expression and altered
subcellular localization. However, it is important to point out that
PRH can also have oncogenic activities and like many other factors
involved in tumorigenesis, PRH may play a tumour suppressor role
in early breast cancer development and an oncogenic role at later
time points. This is perhaps likely since PRH regulates the
expression of many growth factors and growth factors and the
impact of changes in PRH activity are likely to vary depending on
both the extracellular environment and the intracellular signalling
milieu. Nevertheless, given the correlation observed between low
PRH mRNA levels and poor breast tumour survival as well as the
changes in PRH localization and activity in DCIS and IBC, we
propose that monitoring PRH protein levels or activity could be
particularly important for assessing breast tumour prognosis.
In addition, since PRH is known to be important in multiple cell
types, this work has important implications for other types of
cancer.
MATERIALS AND METHODS
Expression vectors and reporters
pMUG1-Myc-PRH expresses human PRH tagged with the Myc9E10
epitope.30 Lentiviral constructs expressing IPTG-inducible PRH shRNA or
control shRNA (Sigma, St Louis, MO, USA) are described in Kershaw et al.12
Adenoviral construct expressing Myc-PRH is described in Souﬁ et al.31
Cell culture, PRH knockdown and transient transfection
Culture and transfection of MDA-MB-231 and MCF-7; early passage cells
obtained from ATCC (Manassas, VA, USA).12 PRH KD and lentiviral infection
and induction of IPTG-inducible PRH shRNA in MCF-7 cells has been
described previously.12 Brieﬂy, MCF-7 cells were transduced using a control
lentivirus that activates RNA-induced silencing complex and the RNA
interference pathway but does not target any known gene or a lentivirus
expressing PRH shRNA. shRNA expression was then induced using IPTG for
7 days. In both cell lines multiple independent KD and control cell lines
were generated using the same vectors and MCF-7 control and KD cells
were used following 7 days of IPTG induction with 1 mM IPTG.
Quantitative reverse transcriptase-mediated PCR (RT–qPCR)
RNA was puriﬁed 7 days post-IPTG induction.10,32 Quantitative PCR was
performed in triplicate with gene of interest and glyceraldehyde-3-
phosphate dehydrogenase primers (Supplementary Table S1). Data
analysis: Rotorgene software, Qiagen, (Rotor-gene Q 5plex HRM),
glyceraldehyde-3-phosphate dehydrogenase mRNA was used as an
internal control and fold change was analysed by the efﬁciency adjusted
quantitative PCR method.
Western blotting and immunostaining
Westerns. Whole-cell extracts were prepared as described33 and 20 μg
total protein was loaded. PRH antibodies have been described
previously.30,32 Lamin A/C and Tubulin were used as loading controls;
these and secondary antibodies were from Santa-Cruz Biotechnology, Inc.
(Dallas, TX, USA). Densitometry was performed using ImageJ software
(NIH, Bethesda, MD, USA).
Immunohistochemistry
Immunohistochemistry was performed on formalin-ﬁxed parafﬁn-
embedded human breast tissues (normal, DCIS, carcinoma). Tissues were
ethically obtained from the Queen Elizabeth Hospital and University
Birmingham pathology archive through the Human Biobank Repository
Centre. The tissues were stained with the Vector ImmPress Excel
anti-mouse Ig or anti-rabbit Ig peroxidase kits (MP-7602 or MP-7601,
respectively, Vector Labs, Burlingame, CA, USA) and visualized with the
ImmPact NovaRed peroxidase substrate (Vector Labs) according to the
manufacturer’s instructions. Staining was performed was follows: tissues
were dewaxed in xylene (PFM Medical, Poynton, Cheshire, UK) and then
rehydrated in graded alcohols (VWR, Lutterworth, Leicestershire, UK) and
then distilled water. Antigen retrieval was performed with high pH buffer
(Vector Labs) and the sections were incubated in Bloxall solution (Vector
Labs) for 10 min at 20 °C to block endogenous peroxidase activity and then
in 2.5% horse serum (Vector Labs) for 20 min at 20 °C. The primary
antibodies (monoclonal mouse anti-human PRH (M6) 1:2000 or polyclonal
rabbit anti-human phosphoPRH (YKN5) 1:3000) diluted in 2.5% horse
serum were added to the sections and incubated overnight at 4 °C. The
sections were then washed in Tris-buffered saline pH 7.2 for 5 min and
incubated with ampliﬁer antibody for 15 min at 20 °C. After washing in
Tris-buffered saline pH 7.2 for 5 min the sections were incubated with the
ImmPress Excel tertiary antibody for 30 min at 20 °C. The sections were
washed in Tris-buffered saline pH 7.2 for 5 min and the NovaRed
peroxidase substrate was added for 5 min. The reaction was stopped by
washing in distilled water for 5 min and the sections counterstained using
Mayers haematoxylin (PFM Medical) for 30 s. The sections were mounted
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using DPX (Cell Path, Newtown, Powys, UK) and left to dry before being
visualized on an Olympus BX53 microscope (Olympus, Southend-on-Sea,
Essex SS2 5QH, UK) with an Olympus SC100 Camera. IHC data were
analysed by categorizing PRH or pPRH expression staining intensity as very
weak, weak, intermediate and strong. Number of PRH or pPRH nuclei
stained in relation to total cell number was categorized as low (0–10%),
intermediate (11–70%) and high (71–100%). Statistical analysis of IHC
intensity and percentage staining was performed using Kruskal–Wallis
tests for categorical data of normal vs DCIS vs pooled carcinoma. For any
test with Po0.05 post hoc Wilcoxon–Mann–Whitney tests were performed
with Bonferroni corrections of Mann–Whitney P-values for multiple
comparisons. The corrected P-values are reported.
Microarrays
RNA from three independent control (C1–C3) and PRH KD (KD1–KD3)
MCF-7 cell lines, extracted 7 days post-IPTG induction using a RNeasy mini
kit (Qiagen, Manchester, UK), was used for double-stranded cDNA
synthesis (Roche Products Limited (Pharmaceuticals), Welwyn Garden
City, UK). cDNA was labelled with Cy3 (NimbleGen One-Color DNA
labelling kit) then hybridized to a Roche NimbleGen 12× 135 K gene
expression microarray. The array was washed and scanned using the MS
200 Microarray Scanner. Data were extracted and normalized by robust
multi-array analysis using DEVA software (v1.2.1). Genes showing
signiﬁcantly altered expression were identiﬁed by statistical analysis of
microarray analysis using MeV software (v4.9). Gene lists were generated
for signiﬁcantly different expression levels using fold change greater than
1.5 and false discovery rate-adjusted P-values of o0.05. For over-
expression microarray experiments RNA from cells infected in three
independent experiments with empty Adenovirus or Adenoviral-PRH (moi
50) was extracted 48 h after infection. RNA production, cDNA labelling and
hybridization, washing and SAM microarray analysis were performed
exactly as described for the KD cells.
Cell counting and proliferation assays
Cell counting and MTT assays as described in Noy et al.10 Cells were
incubated with MTT for 2 h, solubilized with dimethyl sulfoxide and optical
density was measured at 540 nm. For BrdU staining cells (5 × 105) adhered
to coverslips were incubated with 10 μM BrdU (Sigma) for 6 h and then
ﬁxed with 4% w/v formaldehyde. Endogenous peroxidase activity was
blocked with 3% v/v H2O2 (Sigma) and then DNA denatured using 2 M HCl
(Sigma). Cells were incubated with murine anti-BrdU antibody (Sigma)
(1:500 in 1% w/v bovine serum albumin+10% v/v horse serum) overnight,
followed by biotinylated horse anti-mouse IgG (Vector Laboratories)
for 30 min and ﬁnally with Extravadin-peroxidase (Sigma) for 30 min.
Cells were stained with 3,3′-diaminobenzidine solution (Sigma) and then
counted.
Tumoursphere assays
For mammosphere formation cells (1 × 104 or 2 × 104) were plated in poly-
HEMA (Sigma)-coated six-well plates containing Mammocult medium plus
proliferation supplements (Stem Cell Technologies, UK Ltd., Waterbeach,
Cambridge, UK) and cultured at 37 °C in 5% CO2. Seven days later primary
mammospheres larger than 50 μm were counted on a graticule. Mammo-
spheres were trypsinized to a single-cell suspension through a 25G needle
and 2× 104 cells were re-seeded. Secondary mammospheres were counted
seven days later. Limited dilution analysis was performed as outlined in
Rota et al.21
Flow cytometry
Cells resuspended in 100 μl phosphate-buffered saline were stained for
15 min with CD24-FITC and CD44-TRITC or CD133-APC (BD Biosciences,
G44-26) and then analysed using a FACS Analyser Cyan ADP (Beckman
Coulter, Brea, CA, USA).
4T1L syngeneic tumour model
4T1 cells were infected with a ﬁreﬂy luciferase and puromycin resistance-
containing retrovirus MSCV-Luc.34 Infected cells were incubated with
puromycin (8 μg/ml) to select for cells with high puromycin resistance and
high luciferase expression. 4T1L cells were infected with Adenoviral-PRH or
empty Adenovirus at MOI 50 for 24 h. Cells were washed 4× with
phosphate-buffered saline, trypsinized, washed and resuspended in Opti-
mem (Invitrogen, Life Technologies Ltd, Paisley, UK) at 1.25× 106 cells/ml
and kept on ice for 20–30 min before injection. Aliquots 200 μl/2.5 × 105 of
the cells were injected into the no. 3 fat pad of 6- to 8-week-old female
BALB/C mice. Experiments with animals were carried out in accordance
with animal care guidelines (Birmingham University) and with home ofﬁce
requirements (Licence number, PPL 40/3339).
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